healthprotocol.wiki
Protocols
Evidence
Outcomes
Home
/
Protocols
medication-cancer-teclistamab-daratumumab
Outcomes
01
survival-overall-proportion-cohort-measured
1 evidence row
mateos-mv_2025_rct_teclistamab-plus-daratumumab-vs-daratumumab-triplets-in-rrmm-majestec-3
02
survival-progression-free-at-5-years-proportion-cohort-measured
1 evidence row
mateos-mv_2025_rct_teclistamab-plus-daratumumab-vs-daratumumab-triplets-in-rrmm-majestec-3
healthprotocol.wiki